# To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

> **NCT07245251** · NA · NOT_YET_RECRUITING · sponsor: **Starna Therapeutics** · enrollment: 11 (estimated)

## Conditions studied

- Acute Lymphobkastic Leukemia

## Interventions

- **DRUG:** STR-P004

## Key facts

- **NCT ID:** NCT07245251
- **Lead sponsor:** Starna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-11-02
- **Final completion:** 2026-12-30
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07245251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07245251, "To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07245251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*